Therapy of Inflammatory Bowel Disease using 5-Aminosalicylic Acid, 4-Aminosalicylic Acid and Olsalazine Retention Enemas: Review of Clinical Trials
The knowledge that 5-aminosalicylic acid (5-ASA) is the active compound of sulphasalazine and that it acts topically has stimulated the use of 5-ASA containing enemas and ocher similar compounds such as olsalazine and 4-aminosalicylic acid (4-ASA). 5-ASA enemas have been shown to be effective in con...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1989-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/1989/768562 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The knowledge that 5-aminosalicylic acid (5-ASA) is the active
compound of sulphasalazine and that it acts topically has stimulated the use of
5-ASA containing enemas and ocher similar compounds such as olsalazine and
4-aminosalicylic acid (4-ASA). 5-ASA enemas have been shown to be effective in
controlling active disease in clinical trials and have also been shown to be of
benefit in prevention of relapses. Olsalazine enemas have not demonstrated significantly better results than placebo 4-ASA enemas are effective but the results
obtained have differed as to effective dose |
|---|---|
| ISSN: | 0835-7900 |